Vera Therapeutics Inc [VERA] stock is trading at $22.70, down -25.89%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VERA shares have gain 19.79% over the last week, with a monthly amount glided 0.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on February 04, 2025, and set its price target to $49. On January 28, 2025, Goldman initiated with a Buy rating and assigned a price target of $58 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $70 on November 21, 2024. Scotiabank initiated its recommendation with a Sector Outperform. Oppenheimer started tracking with a Outperform rating for this stock on January 25, 2024, and assigned it a price target of $26. In a note dated January 08, 2024, Cantor Fitzgerald initiated an Overweight rating.
Vera Therapeutics Inc [VERA] stock has fluctuated between $18.53 and $51.61 over the past year. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $22.70 at the most recent close of the market. An investor can expect a potential return of 186.34% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.41 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.09 points at the first support level, and at 19.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.73, and for the 2nd resistance point, it is at 24.76.
Ratios To Look Out For
For context, Vera Therapeutics Inc’s Current Ratio is 27.30. Further, the Quick Ratio stands at 27.30, while the Cash Ratio is 2.52.
Transactions by insiders
Recent insider trading involved Fordyce Marshall, PRESIDENT AND CEO, that happened on Feb 21 ’25 when 10613.0 shares were sold. PRESIDENT AND CEO, Fordyce Marshall completed a deal on Feb 26 ’25 to sell 9075.0 shares. Meanwhile, Director MARSHALL FORDYCE bought 9075.0 shares on Feb 26 ’25.
